Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 F...( Statistically Significant Data Detai...),Health

Statistically Significant Data Detailed at a Late-Breaking Presentation at

ICAAC Meeting

CHICAGO and GAITHERSBURG, Md., Sept. 18 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that travelers who received the company's patch-based travelers' diarrhea vaccine were significantly less likely to be sickened as compared with travelers who receive a placebo, according to research presented today by Chief Scientific Officer Gregory Glenn, M.D. at a late-breaker presentation during the "Vaccines and Pediatric Infections" session of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy being held in Chicago.

"We have demonstrated that vaccinated travelers can dramatically cut their risk of diarrhea by using our needle-free patch," said Dr. Glenn, Iomai's founder. "Those who received the Iomai vaccination were much less likely to get sick, and those who were sickened had far milder illness than those who received a placebo. These are clinically significant results that suggest that the patch vaccine will address the most significant unmet need for travel medicine: prophylaxis for travelers' diarrhea."

The study found that of the 59 individuals who received the novel, patch-based vaccine, only three suffered moderate or severe diarrhea, while 23 of the 111 who received a placebo suffered moderate or severe diarrhea, a 75 percent reduction (p=0.007). One of the 59 volunteers in the vaccine group reported severe diarrhea, compared with 12 of the 111 in the placebo group, an 84 percent reduction (p=0.033).

"The results presented at ICAAC are the most robust ever shown in the prevention of travelers' diarrhea, and they suggest we ma
'/>"/>